Last reviewed · How we verify

Bupivacaine Hydrochloride and Lidocaine

Atlantic Health System · FDA-approved active Small molecule Quality 5/100

Bupivacaine Hydrochloride and Lidocaine is a Small molecule drug developed by Atlantic Health System. It is currently FDA-approved. Also known as: Marcaine and Lidocaine, ESP block.

At a glance

Generic nameBupivacaine Hydrochloride and Lidocaine
Also known asMarcaine and Lidocaine, ESP block
SponsorAtlantic Health System
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bupivacaine Hydrochloride and Lidocaine

What is Bupivacaine Hydrochloride and Lidocaine?

Bupivacaine Hydrochloride and Lidocaine is a Small molecule drug developed by Atlantic Health System.

Who makes Bupivacaine Hydrochloride and Lidocaine?

Bupivacaine Hydrochloride and Lidocaine is developed and marketed by Atlantic Health System (see full Atlantic Health System pipeline at /company/atlantic-health-system).

Is Bupivacaine Hydrochloride and Lidocaine also known as anything else?

Bupivacaine Hydrochloride and Lidocaine is also known as Marcaine and Lidocaine, ESP block.

What development phase is Bupivacaine Hydrochloride and Lidocaine in?

Bupivacaine Hydrochloride and Lidocaine is FDA-approved (marketed).

Related